Neuropsychiatric Disorders

Navigating Mild Depression: Early Treatment, Psychotherapy, Antidepressants

by

Minor or subthreshold depression causes significant suffering and impairment, despite falling short of a major depression diagnosis. Effective early treatment is crucial to alleviate symptoms, improve functioning, and prevent progression to major depression. Both psychotherapy and antidepressants show efficacy, with antidepressants possibly having a slight advantage. In a shared decision-making model, patient preferences and values …

Read more

Methamphetamine Dependence Linked to Parkinson’s Disease Risk

by

New research reveals that people with a history of methamphetamine dependence face a startling elevated risk of developing Parkinson’s disease or related movement disorders later in life. Key Facts: Individuals dependent on methamphetamine had almost 3 times the rate of Parkinson’s outcomes compared to matched controls from the general population. For women with methamphetamine dependence, the risk …

Read more

Comparing Depression Treatments for Adults: Antidepressant Drugs, Talk Therapy (CBT), & Other Non-Drug Interventions

by

A large review of research found that talk therapy works about as well as antidepressant medications for treating depression. The study also looked at other non-drug options, like exercise. While benefits were similar across treatments, side effects differed. Key Facts: Cognitive behavioral therapy (CBT) achieved comparable results to medications for treating major depression. Remission rates …

Read more

NLRP3 Inflammasome & Depression: Antidepressant Potential with Targeted Therapy?

by

The NLRP3 inflammasome is increasingly being recognized as a mediator between inflammation and depression. Targeting this molecular complex shows promise for developing new antidepressant therapies. Key Facts: The NLRP3 inflammasome is made up of NLRP3, ASC, and caspase-1 proteins that trigger inflammatory responses when activated. Evidence shows the NLRP3 inflammasome is overactivated in the brains …

Read more

BPC-157 Peptide May Treat CNS Disorders: Stroke, Schizophrenia, Spinal Cord Injury

by

The naturally occurring peptide BPC 157 shows potential to treat stroke, schizophrenia symptoms, and spinal cord injury in animal models. Key facts: BPC 157 rapidly counteracted stroke damage and led to full recovery of memory, coordination and movement in rats. The peptide alleviated schizophrenia-like symptoms and catalepsy in rodent models by modulating dopamine, glutamate and …

Read more

Improving Addiction Treatment by Targeting Cognitive Deficits

by

People struggling with substance use disorders often have difficulties with memory, attention, planning, and decision-making. New research explores how these cognitive deficits relate to treatment outcomes and whether targeting them could improve addiction recovery. Key Facts: Cognitive deficits are common in people with substance use disorders, especially relating to memory, attention, self-control, and reward-based decision-making. …

Read more

Ketamine’s Long-Lasting Antidepressant Effects via “Trapping” in NMDA Receptors & LHb

by

Researchers uncover a surprising molecular mechanism that explains ketamine’s exceptionally long-lasting antidepressant effects. Key Facts: Ketamine’s antidepressant effects last for days after its concentration drops to low, ineffective levels only an hour after administration. This contrasts starkly with ketamine’s short 13-minute half-life in the body. Ketamine continues blocking NMDA receptors and suppressing activity in the …

Read more

Exercise as an Antidepressant: The Best Natural Treatment for Depression?

by

Depression is one of the most common mental health issues, affecting over 320 million people globally. Research shows that exercise may be an effective treatment option for many battling this disabling condition. Key Facts: Exercise has comparable antidepressant effects to medications and psychotherapy in clinical trials. Both aerobic and resistance training reduce depressive symptoms, with …

Read more

Best Antidepressants for Preventing Relapse in Major Depression (Latest Research)

by

Researchers conducted a comprehensive analysis comparing 20 antidepressants to identify the most effective options for preventing relapse in patients with major depressive disorder (MDD). Their findings suggest desvenlafaxine, paroxetine, venlafaxine and vortioxetine balance efficacy and tolerability best for maintenance treatment. Key Facts: The analysis included 34 high-quality clinical trials with over 9,300 patients total. All …

Read more

Revolutionizing Depression Treatment: Novel Rapid-Acting Antidepressants & Emerging Drug Targets

by

Major depressive disorder (MDD) is a global health crisis affecting over 300 million people. While available antidepressants help some patients, treatment is far from satisfactory for many. Exciting research into rapid-acting agents like ketamine and psilocybin combined with exploration of novel drug targets finally offers real hope for transformational change in how depression is treated. …

Read more

+ Load more